Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Canonical Wnt Signaling Pathway

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...

Canonical Wnt Signaling Pathway

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...

Non-Canonical Wnt Signaling Pathways

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...

Non-Canonical Wnt Signaling Pathways

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

Catenins

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026

Same author

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.

International journal of clinical oncology·2026

Same author

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results.

Psycho-oncology·2026

Same author

Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature.

Hereditary cancer in clinical practice·2026

Same author

Genomic Therapy Matching in Rare and Refractory Cancers.

JAMA oncology·2026

Same journal

Bronchiolar adenoma-like lesions with atypical features beyond the classic morphological spectrum: integrating histomorphology and molecular profiles.

The Journal of pathology·2026

Same journal

Differences between mitotically old and young endometrial tumors.

The Journal of pathology·2026

Same journal

Knowledge gaps in tubular gut tumours: a critical appraisal of the 6th edition of the World Health Organization classification of tumours.

The Journal of pathology·2026

Same journal

Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights.

The Journal of pathology·2026

Same journal

Lipodystrophy and adipose tissue recovery are mediated by the Wnt/lipogenesis axis during skin fibrosis.

The Journal of pathology·2026

Same journal

Optical mapping reveals a higher level of large-scale structural variants in a family with paternally transmitted myotonic dystrophy and independent Parkinson's disease.

The Journal of pathology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

The Soft Agar Colony Formation Assay

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Wnts, bone and cancer.

David M Thomas¹

¹Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. david.thomas@petermac.org

The Journal of Pathology

|November 6, 2009

Summary

This summary is machine-generated.

The Wnt pathway is inactivated in bone cancers, contrary to its known role in other cancers. This discovery may lead to new bone-building therapies.

More Related Videos

Modeling Paracrine Noncanonical Wnt Signaling In Vitro

Modeling Paracrine Noncanonical Wnt Signaling In Vitro

Published on: December 10, 2021

Related Experiment Videos

Last Updated: Jun 19, 2026

The Soft Agar Colony Formation Assay

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Modeling Paracrine Noncanonical Wnt Signaling In Vitro

Modeling Paracrine Noncanonical Wnt Signaling In Vitro

Published on: December 10, 2021

Area of Science:

Oncology
Molecular Biology
Cell Signaling

Background:

The Wnt signaling pathway is crucial for bone development and is often implicated in various cancers.
Previous research predominantly viewed the Wnt pathway as oncogenic across different biological systems.

Discussion:

Cai and colleagues present novel findings indicating Wnt pathway inactivation in bone cancers.
This challenges the established understanding of the Wnt pathway's role in oncogenesis.

Key Insights:

The Wnt pathway's role in osteosarcoma appears to be complex and context-dependent.
Inactivation of the Wnt pathway in bone cancers suggests potential therapeutic targets.

Outlook:

These findings necessitate further investigation into Wnt signaling in bone cancers.
The results could pave the way for developing Wnt agonists as bone anabolic agents.